Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Liver physiology and pathology, and Mesenchymal stem cell research.
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease
Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD
From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD
NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD
Association between longitudinal weight change and clinical outcome in individuals with MASLD
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries
Cardiovascular Risk Assessment Tools are Insufficient for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
IDDF2025-ABS-0058 Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in metabolic dysfunction-associated steatotic liver disease
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 <scp>ESSENCE</scp> Trial
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease
acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
A global research priority agenda to advance public health responses to fatty liver disease
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis